Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Tempus AI logo — Tempus AI, Inc. (NASDAQ: TEM) is a technology company leadin...

Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is a technology company leading the adoption of AI to advance precision medicine.

Founded 2015 United States Chicago, United States 3152 employees Post Ipo Debt Total: $1.64B AI, Biotechnology +2

General Information

Company Name Tempus AI
Founded Year 2015
Location United States Chicago, United States +7
Employees 3152
Industries AI, Biotechnology, Health Care +1
Funding Stage Post Ipo Debt
Social

Get notified when Tempus AI moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 21, 2026

Tempus AI announced an extension of its data license agreement with Recursion, along with a new license agreement for Recursion’s proprietary RNA foundation model, TxFM, to advance precision medicine.

Feature Release Sep 14, 2026

Tempus AI is launching whole-genome sequencing capabilities, expanding beyond targeted gene panels to create a deeper understanding of disease progression and treatment response.

Event Participation Sep 14, 2026

Eric Lefkofsky, Founder & CEO of Tempus AI, joined CNBC to discuss how artificial intelligence is reshaping medicine.

Grant Received Sep 10, 2026

Tempus AI has been selected by Advanced Research Projects Agency for Health (ARPA-H) to develop and validate an autonomous AI agent for heart failure patients.

Major Customer Win Sep 02, 2026

Tempus AI secured Zentalis Pharmaceuticals as a customer, who utilized Tempus Lens and its integrated workspace for their pipeline.

Product Launch Sep 01, 2026

Tempus AI has launched Lens Workspaces, a seamless environment that helps researchers train custom AI agents on past research and code for faster insights.

+1 more signal in last 30 days

Get alerts when Tempus AI shows new signals

About Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is at the forefront of integrating artificial intelligence into the healthcare sector, emphasizing the power of precision medicine. Since its founding in 2015, Tempus has focused on building one of the largest libraries of multimodal medical data globally, ensuring that every patient's treatment is informed by the accumulated experience of those before them.

Headquartered in the United States, Tempus operates within a dynamic intersection of AI, Biotechnology, Health Care, and Machine Learning. Its AI-enabled systems are designed to empower physicians with personalized care capabilities while bolstering therapeutic discoveries and developments.

A recent influx of $300.00 million through a Post-IPO Debt investment on 19 February 2025, led by Ares Management, highlights the continued confidence in Tempus's innovative edge and market potential.

Taxonomy: Precision Medicine, Multimodal Data, Clinical Data Interpretation, Molecular Data Analysis, Personalized Patient Care, Therapeutics Development, AI-Enabled Healthcare Solutions, Patient Data Utilization, Healthcare Operating Systems, Medical Data Libraries, Healthcare Innovation

Services & Products

AI-Enabled Healthcare Solutions
Diagnostic Tools Development
Healthcare Data Analytics
Research Program Partnerships

Target Customers

Healthcare Providers Research Institutions Medical Professionals Healthcare Researchers

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 1
Investor
19 Feb 2025
Series G •••••• 1
Investor
12 Oct 2023
Venture Round •••••• - 20 Oct 2022
Debt Financing •••••• 1
Investor
20 Oct 2022
Series G •••••• 5
Investor Investor Investor Investor
•••• •••• 		10 Dec 2020

View All 15 Funding Rounds

Latest News

View All
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdo... — Cnbc
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Cnbc Dec 24, 2024
Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company's Next Chapter o... — Biospace.com
Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company's Next Chapter of Commercial Growth and Product Innovation
Biospace.com Apr 09, 2025
AI craze is distorting VC market, as tech giants like Microsoft and Amazon pour in billions of dolla... — Cnbc
AI craze is distorting VC market, as tech giants like Microsoft and Amazon pour in billions of dollars
Cnbc Nov 23, 2025
Robinhood is raising $2 billion in zero-coupon convertible bonds to buy back stock — Thenextweb
Robinhood is raising $2 billion in zero-coupon convertible bonds to buy back stock
Thenextweb Jun 22, 2026
Tempus AI, kanser takibi teknolojilerini güçlendirmek için Personalis’i 1,5 milyar dolara satın alıy... — Webrazzi
Tempus AI, kanser takibi teknolojilerini güçlendirmek için Personalis’i 1,5 milyar dolara satın alıyor
Webrazzi Jul 21, 2026

Tempus AI Alternatives & Competitors

View All Alternatives
Tempus AI vs
datma
datma United States

Unleashing the potential of healthcare data

Grant
50 employees
AI, Analytics
Compare Tempus AI vs datma
Tempus AI vs
Imagene AI
Imagene AI United States

A Cross-Modality Intelligence Engine for Precision Medicine

37 employees
Tempus AI vs
Alacrity
Alacrity United States

The enabler of immunotherapy cures to patients || Precision Management for Precision Medicine

12 employees
Health Care, Health and Wellness
Also compare with: Tempus AI vs Mango Sciences Mango Sciences Tempus AI vs Perspectum Ltd Perspectum Ltd View all alternatives

FAQ About Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is a technology company leading the adoption of AI to advance precision medicine.
Tempus AI was founded in 2015.
Tempus AI is headquartered in Chicago, United States.
Tempus AI operates in the following industries: AI, Biotechnology, Health Care, Machine Learning.
Tempus AI has approximately 3152 employees.
Tempus AI has completed 15 funding rounds, raising a total of $1.64B. The latest funding stage is Post Ipo Debt.
Tempus AI offers: AI-Enabled Healthcare Solutions, Diagnostic Tools Development, Healthcare Data Analytics, Research Program Partnerships.
Top alternatives and competitors to Tempus AI include datma, Imagene AI, Alacrity, Mango Sciences, Perspectum Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tempus AI and datma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Tempus AI and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes